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1 Introduction 
1.1 Background  
Infection with hepatitis B and C virus (HBV and HCV, respectively) affects the liver and results in a broad spectrum 
of disease outcomes. An infection with HBV can spontaneously resolve and lead to protective immunity, result in a 
chronic infection and, in rare cases, cause acute liver failure with a high risk of dying. In contrast to HBV, an 
infection with HCV becomes chronic in most cases1. People with chronic hepatitis B and/or C virus infection remain 
infectious to others and are at risk of serious liver disease such as liver cirrhosis or hepatocellular cancer (HCC) 
later in life2, 3. HBV infection is widely present: approximately one third of the world’s population has been exposed 
to the virus, and an estimated 350 million people are chronically infected4, 5. More than 500 000 people die each 
year of hepatitis-B-related diseases4, 6. The World Health Organization estimates that two to three percent of the 
world’s population are infected with HCV, resulting in a total number of 120 to 170 million people7, 8 .There is a 
distinct geographical variation in both HBV and HCV prevalence and incidence in the European Union and 
neighbouring countries. 
1.2 Rationale for the study 
Over the past decade, the possibilities for antiviral treatment of chronic HBV and HCV infection have greatly 
improved, e.g. there are now six registered drug therapies for chronic HBV, and several new registrations are 
expected in the near future. This offers the possibility of secondary prevention of HBV- and HCV-related diseases, 
as antiviral treatment can improve disease outcome9, 11, even though concerns regarding the effectiveness of 
treatment on clinical outcomes and resistance exist and combination therapy may be warranted12, 13. Evidence is 
accumulating that recently developed antiviral therapies may provide a cost-effective intervention to reduce 
morbidity and mortality in patients with HBV14-18.  
However, as hepatitis B and C are largely asymptomatic, many patients who might benefit from treatment remain 
undetected. This raises the question whether an active effort should be undertaken to identify chronic HBV and 
HCV carriers so that they can be offered treatment. This would benefit patients and reduce the burden of illness 
and costs for the healthcare system, as costly sequelae and deaths could be prevented among a large proportion 
of those infected19, 20. In addition, this may reduce transmission of HBV and HCV through a reduction of the 
infected pool (by curing a proportion of cases through treatment), by reducing the viral load and therefore the 
infectivity of chronic carriers, and by offering increased opportunities to vaccinate susceptible contacts of identified 
HBV carriers.  
The improved options for antiviral treatment now offer the possibility of successful secondary prevention of HBV 
and HCV. This raises the question whether there is a need to extend screening for chronic HBV and HCV infection 
to those population subgroups with the highest prevalence. 
In order to promote national and European policies on secondary prevention of HBV and HCV, a systematic 
assessment of the need for HBV and HCV screening is required. This consists of at least two initial steps: an 
estimation of HBV and HCV prevalence (including the burden of disease in European countries), and an assessment 
of the effectiveness of current national screening policies. Subsequent steps include an assessment of stakeholder 
perceptions, and the identification of possible interventions and resource implications, together with required 
monitoring programmes21. 
The goal of this literature review is to obtain insight into HBV and HCV prevalence, burden of disease, and national 
screening policies and their effectiveness in EU countries.  
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2 Literature review  
A systematic literature review was carried out by first framing the study questions. Second, a search strategy for 
each question was specified. Subsequently, the searches were carried out and publications of interest were 
selected, based on titles and abstracts. The full text of all selected publications was assessed for relevance. This 
was followed by extracting the relevant data from the identified publications according to the steps described in 
detail below. Thirty-four countries are included in the literature review: 27 EU Member States, Norway, Iceland, 
Liechtenstein, Switzerland and the three EU candidate countries (Croatia, the former Yugoslav Republic of 
Macedonia, and Turkey). The methodology used for the analysis of the literature is described separately (see 
review questions in Annex 2). 
2.1 Research questions  
The burden of disease of HBV and HCV due to chronic infection and screening effectiveness was elaborated in five 
research questions.  
1. What is the prevalence of chronic HBV and HCV infection in the general population and in the following sub-
populations?  
• Blood donors 
• Pregnant women 
• Drug users (DUs) 
• Men having sex with men (MSM) 
• Migrants 
Chronic HBV and HCV infection is defined by the detection of HBsAg and anti-HCV antibodies, respectively. The 
assessment of the prevalence of HBV and HCV among blood donors is restricted to first-time donors. Blood donors 
are generally selected to have a low prevalence of blood-borne infections. This can be regarded as the lower limit 
of the prevalence estimate in the general population. The prevalence in repeat donors is considered to be less 
relevant for the assessment of the burden of HBV and HCV in Europe and was therefore not included in this review. 
2. What is the number of individuals with chronic HBV or HCV infection?  
• Calculations are based on general population prevalence (the number of chronic infections is the prevalence 
of chronic infection times the population size). 
• The number of chronic infections in the three largest nationality groups of first generation migrants (a 
foreign-born person that has migrated to the country of current residence, excluding expatriate children). 
The number of chronic HBV and HCV infections in these groups will be estimated for each country, if data 
are available, by multiplying the number of individuals in the three largest first-generation migrant groups 
born in medium or high endemic countries22, 23 with the median prevalence in mid- and high endemic 
countries, respectively. Data on global prevalence of chronic HBV and HCV infection will be used, if available, 
from Marschall et al.24 and from WHO and Perz et al.7, 8, respectively. 
3. What is the burden of HBV- and HCV-related cirrhosis and hepatocellular carcinoma (HCC)?  
• What is the burden of disease, defined as morbidity and mortality due to cirrhosis and HCC?  
• What is the proportion of the burden of cirrhosis and HCC that is attributable to chronic HBV and HCV 
infection?  
4. What is the current national practice regarding screening for chronic HBV and HCV infection in: 
• pregnant women; 
• blood donors; 
• migrants; 
• IDUs; and 
• MSM? 
5. What is the effectiveness of these screening programmes in terms of: 
• process (coverage of the programme and the proportion of the risk group screened); 
• outcome (proportion of screened individuals which are HBsAg or anti-HCV positive);  
• outcome (proportion of positive individuals who are receiving care);  
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• prevention of secondary cases (what proportion of contacts of HBsAg-positive individuals detected through 
screening is vaccinated?); and 
• cost-effectiveness: what is the cost effectiveness of these screening programmes? 
2.2 Literature research 
A selection of relevant studies was performed. Following the identification of studies in literature databases using 
specific search strategies and inclusion criteria, a list of search terms (free and MeSH terms of each database) and 
a specific search-term combination was defined, including all 34 EU/EFTA country names (see Annex 1–3). 
The three databases that were searched using these search-term combinations were MEDLINE (Ovid), EMBASE, 
and SciSearch. The reference lists of all included publications were reviewed as well. The latter could also include 
public health reports. The search was performed in two phases: first MEDLINE was searched using the Ovid 
interface, followed by a search of EMBASE and SciSearch.  
Inclusion and exclusion criteria for this review were: 
• Only English-language publications were included.  
• Publications published between 1 January 2000 up to the date of the search (August 2009) were included. 
• Only publications published in peer-reviewed journals and public health reports cited in these journals were 
included. 
• Public health reports were included if published in English and downloadable or obtainable by other means 
within ten days.  
Each study that met the above inclusion criteria was judged as to whether it was expected to contain data relevant 
to each of the research questions. This was done based on title and abstract. To check consistency between both 
reviewers, a selection of publications was judged by both reviewers and discrepancies were discussed. As 
consistency was high, the publications were divided between both reviewers. In case of doubt, a decision was 
made after consulting the other reviewer. Publications were only included it they were expected to contain primary 
data or systematic reviews. 
Complete publications were obtained from available information sources. For each publication, basic data were 
recorded on page one and two of the data extraction form, up to question 12 (Annex 3). When a study was not 
considered relevant and therefore excluded, the reason for exclusion was recorded on the data extraction form. 
For example, publications on the prevalence of infection in blood donors were excluded if it was not specified 
whether the study population contained first-time donors.  
Data for each publication were extracted using data collection forms (Annex 3), specific to each of the detailed 
questions. The form included criteria to judge the quality of the study, such as study design, sampling method, and 
description of the study population. Reviews were kept separate as these could not be summarised by using the 
data extraction form. 
The data extraction forms were then entered in a Microsoft Access database.  
Data were summarised for each country and region (where appropriate). Information from review publications was 
used for example for countries for which our search did not yield relevant studies. 
2.3 Analysis of data  
Prevalence of HBV and HCV infection 
Among the included subpopulations, pregnant women and blood donors are to some extent representative for the 
general population, whereas IDUs, MSM and migrants are specific groups at a higher risk of hepatitis B and C.  
The number of prevalence estimates found for HBC and HCV are summarised by country and presented in maps. 
The prevalence of HBV and HCV in the general population, pregnant women and blood donors are presented in six 
separate maps displaying 34 countries. To derive prevalence estimates per country the following algorithm was 
applied:  
• For the prevalence in the general population, studies that are only based on children are not taken into 
account.  
• If multiple prevalence estimates are available for a country, estimates based on studies that are 
representative for the whole country are preferred.  
• In case of multiple estimates from comparable studies, the average prevalence is calculated and weighted 
by study size.  
• When estimates for three or more regions in a country are available, the estimates are shown per region if 
the difference between regions is more than 0.5%.  
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To assess the HBV prevalence in IDUs, we used data from the 2009 Statistical Bulletin from the European 
Monitoring Centre for Drugs and Drugs Addiction (EMCDDA) 25. The prevalence of HCV among IDUs in the EU was 
taken from two recent literature reviews26, 27. Regarding blood donors, our literature search was complemented by 
a report for the Council of Europe.28  
Number of individuals with chronic HBV and HCV infection 
In order to estimate the number of individuals with chronic HBV and/or HCV the estimate for the general 
population prevalence must be multiplied by the population size obtained from Eurostat (as of January 1, 2009) 22. 
To obtain further insight in the number of individuals with chronic HBV and HCV, the number of individuals in the 
three largest first-generation migrant (FGM) groups born in medium- and high-HBV-endemic countries were 
multiplied by the median HBV and HCV prevalence of mid- and high-endemic countries, respectively. The three 
largest groups of FGMs from mid- and high-HBV-endemic countries in each country was obtained from the 
Organisation for Economic Co-operation and Development (OECD) 23 and from Eurostat22 if there was no 
information available from OECD. For each country, the most recent population size estimates were used. Each 
FGM group was classified as mid- or high-endemic for HBV, according to the WHO classification for HBV 
(Figure 1)29. The associated prevalence was then multiplied by the number of individuals in each group to obtain 
the estimated number of infected individuals. 
Figure 1. Geographical distribution of HBV endemicity  
 
Red: High (HBsAg prevalence ≥8% 
Orange: Intermediate (HBsAg prevalence 2%–7%) 
White: Low (HBsAg prevalence <2%) 
Source: World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services. Management 
guidelines, including information for health workers and parents. Geneva: WHO; 2001. 
The burden of HBV- and HCV-related cirrhosis and hepatocellular carcinoma  
The assessment of the burden of HBV- and HCV-related disease was limited to mortality. The rationale for this is 
that reliable data on the incidence of cirrhosis are not available due to the lack of a consensus on case definitions 
and registrations. For HCC, mortality is a close proxy of incidence as the survival period is limited. To assess the 
mortality of HBV- and HCV-related cirrhosis and HCC, the method described by Perz was used30. Firstly, data on 
the overall mortality due to cirrhosis and HCC for males and females were estimated by country. Subsequently, the 
prevalence of anti-HCV and HBsAg was estimated among these patient groups in each country (not estimated 
separately for males and females). These anti-HCV and HBsAg prevalences were multiplied with the mortality 
estimates to assess the HBV- and HCV-attributable burden of cirrhosis and HCC mortality.  
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Screening practices for chronic HBV and HCV infection 
All selected publications were grouped according the target population: screening recommendations for blood 
donors, migrants, pregnant women, drug users, and the general population. In addition to the published literature 
two further publications were reviewed: C. van der Poel’s report for the Council of Europe (September 2009) on 
screening policies for blood donors, and a conference presentation by G. Loeber (Dutch Conference on pre- and 
neonatal screening, April 2009) regarding antenatal screening policies. 
Effectiveness of screening programmes for chronic HBV and HCV infection 
The following indicators were used to provide an overview of the effectiveness of screening programmes, where 
data were available:  
• Proportion of the screened target population (coverage). 
• The proportion of centres offering screening. 
• The prevalence of HBV and/or HCV. 
• The proportion of HBV-susceptible people that are vaccinated and the proportion of contacts of vaccinated 
HBV carriers.  
2.4 Identified citations 
The prevalence of chronic HBV and HCV infection  
The search identified 1759 citations, 984 through MEDLINE, and an additional 775 through EMBASE and SciSearch. 
Of the 984 citations from MEDLINE, 227 (23%) were selected based on title and abstract. For the 775 citations 
from additional databases only the titles were available, on the basis of which 47 (6%) were selected. From the 
reference lists of included studies, another 16 potentially relevant citations were identified based on their titles. For 
items that were selected based on the title alone, abstracts were retrieved and 17 were considered relevant. Finally, 
for a total of 244 citations the full text publication was retrieved and reviewed using the data extraction form. 
Based on the full text, 53 publications were considered not relevant and excluded. Furthermore, 67 publications on 
drug users were excluded since information on the prevalence in this group was obtained from the EMCDDA 2009 
Statistical Bulletin and literature reviews (Figure 2).  
77 estimates for the prevalence of hepatitis B and 68 for the prevalence of hepatitis C were found. Some 
publications reported both HBV and HCV prevalence, and one publication reported results from multiple countries.  
Figure 2. Flowchart: number of publications included in the review of the prevalence of chronic HBV 
and HCV infection in Europe 
 
Note: A similar strategy for identifying relevant publications was used for the other study questions (see text for details). 
Potentially relevant citations identified 
during first search in Medline, Embase, 
SciSearch databases:
n=1759 citations
Studies included in the review:
n=124 publications.
• Original studies: n=114 publications
• Reviews: n=10 publications.
Retrieval of hard copies of potentially 
relevant publications:
n=244 publications.
• Publications identified through 
electronic search: n=236
• Publications identified through review 
of bibliographies: n=8 publications
Citations excluded:
n=1515 citations
Publications excluded:
n=120 publications
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The burden of HBV- and HCV-related cirrhosis and hepatocellular carcinoma  
The search identified 2130 publications, 778 through MEDLINE, and an additional 1352 through EMBASE and 
SciSearch. Of the 778 citations from MEDLINE, 64 (8%) were selected based on title and abstract. For the 1352 
citations from additional databases only titles were available, on the basis of which 23 (2%) were selected. For 
these 23 selected citations, 10 relevant abstracts were retrieved. From the reference lists of included studies, 
another 12 potentially relevant citations were identified. Finally, for a total of 56 citations the full text publication 
was retrieved and reviewed using the data extraction form. Based on the full text, 10 publications were considered 
not relevant and excluded.  
Regarding the overall burden of mortality due to HCC and cirrhosis, the search found an estimate for only four 
countries, and three recent reviews for Europe49-51. These publications were used to extract HCC and cirrhosis 
mortality data. The recent reviews for Europe were based on data from the World Health Organisation Statistical 
Information System database (http://www.who.int/whosis/en/). 
Screening for HBV and HCV infection 
The search on HBV and HCV screening in Europe, its effectiveness and related policies identified 310 citations, 237 
through MEDLINE, and an additional 73 through EMBASE and SciSearch. Of the 237 citations from MEDLINE, 47 
(20%) were selected based on title and abstract. For the 73 citations from additional databases only titles were 
available, on the basis of which 8 (11%) were selected. From the reference lists of included studies, another 2 
potentially relevant citations were identified. For the 10 citations that were selected based on only the title, 5 
relevant abstracts were retrieved. Finally, for a total of 52 citations the full text publication was retrieved and 
reviewed using the data extraction form. Based on the full text, 12 publications were considered not relevant and 
excluded. The 40 included studies reporting on screening practices and/or effectiveness represented only 10 of the 
34 included countries, and were distributed unevenly. Seventeen studies originated from the United Kingdom, six 
from Italy, six from France, three from the Netherlands, two from Ireland and one each from Belgium, Denmark, 
Greece, Hungary and Switzerland.  
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3 Results 
3.1 Prevalence of chronic HBV and HCV infections 
The number of estimates per country for HBV and HCV are presented in Table 1. No recent estimates for the HBV 
and HCV prevalence were available for 13 and 14 countries, respectively. For Italy, a relatively high number of 
estimates were available. Estimates derived from EMCDDA data (HBV in drug users) and from the report for the 
Council of Europe (HBV and HCV in first-time blood donors) are not included in Table 1.  
Table 1. Number of estimates for the prevalence of hepatitis B (HBsAg) and hepatitis C (anti-HCV) 
HBsAg anti-HCV 
Country* Number Country** Number 
Belgium 2 Belgium 2 
Bulgaria 1 Bulgaria 1 
Cyprus 2 Croatia 1 
Czech Republic 1 Cyprus 1 
Denmark 4 Czech Republic 1 
Finland 1 France 1 
France 1 Germany 5 
Germany 6 Greece 6 
Greece 9 Hungary 1 
Ireland 2 Italy 24 
Italy 20 Netherlands 3 
Lithuania 1 Norway 1 
Netherlands 4 Poland 2 
Poland 1 Romania 1 
Romania 1 Slovakia 1 
Slovakia 2 Spain 4 
Spain 3 Sweden 1 
Sweden 1 Switzerland 1 
Switzerland 1 Turkey 4 
Turkey 10 United Kingdom 7 
United Kingdom 4   
* HBV: No recent data for Austria, Croatia, Estonia, the former Yugoslav Republic of Macedonia, Hungary, Iceland, Latvia, 
Liechtenstein, Luxembourg, Malta, Norway, Portugal, Slovenia. 
** HCV: No recent data for Austria, Denmark, Estonia, Finland, the former Yugoslav Republic of Macedonia, Iceland, Ireland, 
Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Portugal, Slovenia. 
The prevalence of HBV and HCV in the general population 
For the prevalence of hepatitis B and hepatitis C in the general population, 38 and 35 estimates were found, 
respectively. A summary of these estimates with information on the methods and population is given in Tables A1 
and A2 (Annex). For HBV, the prevalence in the general population ranged from 0.1% to 7% by country (Figure 
3a). Prevalence estimates that could be considered representative for the entire country were available for ten 
countries: Belgium, Czech Republic, Denmark, Finland, Germany, Greece, Ireland, Italy, Netherlands, Romania, 
Slovakia, and Turkey. Six of these estimates were derived from one study describing the prevalence of chronic HBV 
in several European countries31. For Italy and Turkey regional prevalence estimates could be presented separately. 
The references that were used for calculating the prevalence per country in Figures 3a/3b are marked with an 
asterisk in Table A1. 
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Figure 3a. Hepatitis B prevalence in the general population: HBsAg 
 
 
Figure3b. Hepatitis C prevalence in the general population: anti-HCV 
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For HCV, the prevalence ranged from 0.4% to 3.5% by country and from 0.2% to 10.4% by region within 
countries (Figure 3b). Prevalence estimates that could be considered representative for the entire country were 
available for only three countries: the Czech Republic, Germany and Romania. For Italy, regional prevalence 
estimates could be presented separately. The references that were used for calculating the prevalence per country 
in Figures 3a/3b are marked with an asterisk in Table A2. 
The prevalence of HBV and HCV among blood donors 
Seven estimates on the prevalence of HBV and five HCV were found among first-time blood donors. From a recent 
report for the Council of Europe we obtained estimates for an additional 17 countries for HBV and 18 countries for 
HCV28. All estimates are summarised in Tables A3 and A4. The references that were used for calculating the 
prevalence per country in the map are marked with an asterisk in Tables A3 and A4.  
For HBV, the prevalence in first-time blood donors ranged from 0.0% to 5.2% by country (Figure 4a). In almost all 
countries with prevalence estimates available for both groups, the prevalence in first-time blood donors was lower 
than for the general population, with the exception of Cyprus. Cyprus reported a relatively high prevalence in first-
time blood donors of 3.0%, and a low prevalence of 0.9% in the general population32, 33. However, the general 
population study only included participants aged 0–30 years and may thus not be representative for the general 
population including middle-aged and older adults. For Greece, a large difference was observed between the 0.9% 
prevalence in the study by Zervou34, and the prevalence of 3% reported in the report for the Council of Europe28. A 
possible explanation for this discrepancy might be the proportion of voluntary, non-remunerated donations, which 
was 46% in the Council of Europe report, and 100% in the study by Zervou. 
For HCV, the prevalence in first-time blood donors ranged from 0.02% to 3.3% by country (Figure 4b). The 
prevalence in first-time donors was lower than the prevalence estimate for the general population in all countries 
that had both estimates available.  
Figure 4a. Hepatitis B prevalence in first-time blood donors: HBsAg 
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Figure 4b. Hepatitis C prevalence in first-time blood donors: anti-HCV 
 
The prevalence of HBV and HCV among pregnant women 
Sixteen estimates on the prevalence of HBV and 15 of HCV prevalence were found among pregnant women 
(Tables A5 and A6). The references that were used for calculating of the prevalence per country in the map are 
marked with an asterisk in Tables A5 and A6. 
For HBV, the antenatal prevalence ranged from 0.1% to 4.4% by country (Figure 5a). The prevalence in pregnant 
women was generally higher than in the general population, provided that both estimates were available. This 
applies to Germany, Greece, Ireland, Italy, the Netherlands and Slovakia. This difference in prevalence might be 
connected to the fact that migrant women, which have a relatively high HBV prevalence, are better represented in 
studies among pregnant women than in general population studies. Spain reports the lowest prevalence in 
pregnant women tested in Catalonia in 2004 (0.1%)35, which is lower than the prevalence in the general 
population in the same region in 2002 (0.7%)36. The authors attribute the low prevalence in pregnant women to 
the higher vaccination rate: 16% of pregnant women had serologic markers of vaccination, compared with 8% in 
the general population study.  
For HCV, the prevalence in pregnant women ranged from 0% to 1.7% by country (Figure 5b). The 15 prevalence 
estimates relate to only six countries, and the prevalence estimate for pregnant women in Greece was similar to 
that of the general population (1.2% and 1.0%, respectively). In the UK, the prevalence estimate for pregnant 
women was similar to the prevalence in women in the general population, 0.3% and 0.4% respectively37. The 
prevalence in pregnant women in the north of Italy was estimated at 1.7%, which is lower than the estimated 
prevalence in the general population for that region (3.2%). This might be related to age, since general population 
studies report that HCV prevalence increases with age, with the highest prevalence rates observed in people over 
55 years38,39, 40.  
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Figure 5a. Hepatitis B prevalence in pregnant women: HBsAg 
 
 
Figure 5b. Hepatitis C prevalence in pregnant women: anti-HCV 
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The prevalence of HBV and HCV among migrants and minority groups 
Primary information on the prevalence of HBsAg among migrants and minority populations was published in 12 
publications, seven of which from Italy. One of these publications reported on two migrant groups46. There was a 
wide variation in the HBsAg prevalence, ranging from 1.0% in resident first generation migrants in the Netherlands 
to 15.4% in Albanian refugees in Greece (Table A7). A review by Clark and Mytton regarding infectious diseases in 
UK asylum seekers and refugees found HBsAg prevalences ranging from 5.7 to 9.3%47. The authors conclude that 
the observed variation in prevalence is likely to reflect sampling difficulties. For all countries, the estimated HBsAg 
prevalence among migrants was compared to the prevalence among the general population. The results show that 
for all migrant groups and all countries*
Prevalence of anti-HCV among migrants and minority populations was described in ten publications, four of which 
from Italy. One of these publications reported on two migrant groups46. The anti-HCV prevalence ranged widely 
from 0 to 23.4% (Table A8). The latter percentage refers to a Roma population in Hungary with a large proportion 
of IDUs48. Comparing the estimated anti-HCV prevalence among migrants in a specific country with that of the 
general population in that country, it was shown that for all migrant groups and all countries except Italy, the anti-
HCV prevalence among migrants was higher than that in the general population (Tables A2 and A8).  
, HBsAg prevalence among migrants was higher than in the general 
population (Tables A1 and A7). 
The prevalence of HBV and HCV among injecting drug users (IDUs) 
For the prevalence of HBsAg in IDUs, data from the EMCDDA is summarised in Table A9 
(http://www.emcdda.europa.eu/stats09/inftab114) 25 . For this table, national estimates were included where 
available. When multiple estimates were available, the most recent estimate was included. The reported HBsAg 
prevalence in IDUs varied widely, ranging from 0.0% in Belgium to 11.6% in Bulgaria in 2006. Generally, the 
HBsAg prevalence among IDUs is higher in countries in Central and Eastern Europe, compared with those in 
Western Europe. 
For HCV, 98 studies on HCV prevalence in IDUs in all EU countries except Luxembourg were published between 
1990 and 200026, 27. The review by Mathei et al. identified 66 HCV seroprevalence studies in IDUs published 
between 1989 and 200026, 27. As for the general population estimates, Italy was overrepresented in the number of 
published studies.  
The overall prevalence of anti-HCV and/or RNA positivity among IDUs reported in Roy’s publication was 71% 
(21574/30359), much higher than the prevalence of HBsAg among IDUs. The ranges in the anti-HCV prevalence 
found by Roy and Mathei were very similar: 30% to 98% and 33% to 95%, respectively. Both reviews found that 
prevalence estimates varied widely within countries and concluded that this was mainly due to lack of 
representativeness of sampling methods. Often convenience sampling is used, whereby participants are not 
representative of all current, or past, IDUs. Increasing age, increasing duration of injecting drug use and 
imprisonment were identified as risk factors. However, neither these factors nor temporal trends could explain the 
heterogeneity observed in the anti-HCV prevalence rates. Both studies conclude that HCV is highly prevalent 
among IDUs in Europe.  
The prevalence of HBV and HCV among men who have sex with men (MSM) 
The estimated HBsAg prevalence was 4% in MSM studied in an sexually transmitted diseases (STD) clinic in 
Gothenburg, Sweden in 1993–199741, and lower than 1% in MSM in Scotland, studied in 1993–200342, 43. The 
estimated anti-HCV prevalence was 1.3% among MSM in Amsterdam in 200344, and 2.9% among MSM in seven 
cities in Croatia between 2003–200645. 
3.2 The number of individuals with chronic HBV or HCV 
infection 
The estimated number of persons with chronic HBV and the number of persons with chronic HCV infection based 
on general population prevalence estimates are presented in Table A10; also the numbers in the main migrant 
groups are presented for countries where data were available. Figures 6 and 7 present the number of HBsAg- and 
anti-HCV-positive individuals, respectively, based on general population prevalence estimates. These estimates 
show that Turkey has the largest number of HBsAg-positive individuals; Italy has the largest number of anti-HCV-
positive individuals (Figures 6, 7). Germany has the largest number of infected migrants both for HBsAg and anti-
HCV (Figure 8).  
 
                                                                    
* Excluding the relatively high HBsAg prevalence found in Sardinia. 
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Figure 6. Estimated number of HBsAg-positive individuals by country, based on general population 
prevalence estimates 
  
Figure 7. Estimated number of anti-HCV-positive individuals by country, based on general population 
prevalence estimates 
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Figure 8. Estimated number of HBsAg- and anti-HCV-positive individuals in the three largest migrants 
groups, by country 
 
* No data on anti-HCV prevalence  
3.3 The burden of HBV- and HCV-related cirrhosis and 
hepatocellular carcinoma 
Table A11 and Figure 9 show the estimated HCC mortality rate for males and females by country. Annual HCC 
mortality ranged for women from 0.27 per 100 000 in Sweden to 5.35 per 100 000 in Bulgaria, and for men from 
0.68 per 100 000 in Sweden to 8.03 per 100 000 in Bulgaria. HCC mortality for both males and females is generally 
lower in countries in the north-west of Europe, compared with the south-east. This can be partially attributed to 
the fact that data for some of the countries in Eastern Europe did not distinguish primary and metastatic liver 
cancer (see footnote for Figure 9). The main causes of HCC are HBV and HCV infection, alcohol consumption and, 
to a lesser extent, smoking.  
Table A12 and Figure 10 show the estimated cirrhosis mortality rate for males and females by country. Annual 
cirrhosis mortality ranged for women from 1.02 per 100 000 in Malta to 20.91 per 100 000 in Hungary, and for 
men from 4.4 per 100 000 in the Netherlands to 68.27 per 100 000 in Hungary. Both for males and females, the 
mortality due to cirrhosis is relatively high in some Eastern European countries. However, similar to HCC, some of 
the variation may be due to validity of cirrhosis certification. 
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Figure 9a. Hepatocellular carcinoma related mortality per 100 000 population: men* 
 
 
Figure 9b. Hepatocellular carcinoma related mortality per 100 000 population: women* 
 
* Note: Data for Belgium, Bulgaria, Estonia, Hungary, Latvia, Poland, and Switzerland did not distinguish between HCC and other 
liver cancers. 
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Figure 10a. Cirrhosis-related mortality per 100 000 population: men 
 
 
Figure 10b. Cirrhosis-related mortality per 100 000 population: women 
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Table 2 and Figure 11 list the estimated HBsAg- and anti-HCV prevalence in cases of HCC by country. Data was 
available for only a quarter of countries included in this review (8 of 34, 24%). There is large variation in HBV and 
HCV prevalence among HCC patients in Europe. For HBV, Turkey and Greece have the highest prevalence, while 
Italy ranks first in HCV with an estimated 64% of HCC patients positive for HCV. This pattern is consistent with the 
one observed for HBV and HCV prevalence in the general population.  
Table 3 combines the data on the prevalence of HBV and HCV among patients with HCC with the mortality 
estimates for this condition (Table A11) in order to estimate the HCV- and HBV-related HCC mortality rate for HCC 
in men and women by country (Table 3 and Figure 12). The same is done for cirrhosis in Tables 4 and 5 (Table 
A12). Among the countries where information was available, Italy has the highest HCV- and HBV-related HCC 
mortality rate for both men and women. For HBV/HCV-related cirrhosis mortality, available data was even more 
limited, covering only two countries (Italy and Spain, Table 5).  
Table 2. Estimated anti-HCV- and HBsAg-prevalence in HCC patients by country 
Country 
Anti-HCV prevalence HBsAg prevalence 
% N References % N References 
Italy 64% 1268 52-57 18% 1,701 58, 52-56, 59 
Spain 52% 576 60, 61 17% 576 60, 61 
Austria 38% 245 62 11% 245 62 
Belgium 35% 54 63, 64 23% 500 63, 64 
Turkey 25% 463 65-67 54% 463 65-67 
Germany 21% 386 68, 69 25% 471 68-70 
Sweden 20% 95 71 4% 95 71 
Greece 18% 639 72, 73 57% 639 72, 73 
 
Figure 11. Estimated HBsAg and anti-HCV prevalence in HCC patients by country 
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Table 3. Estimated HCV- and HBV-related HCC mortality rate by country 
Country 
HCV-related HCC mortality 
(rate per 100 000 per year) 
HBV-related HCC mortality 
(rate per 100 000 per year) 
 Men Women Men Women 
Italy 4.28 1.22 1.20 0.34 
Spain 2.54 0.79 0.86 0.27 
Austria 1.59 0.35 0.45 0.10 
Belgium 0.83 0.60 0.54 0.39 
Germany 0.59 0.15 0.71 0.19 
Greece 0.27 0.05 0.88 0.17 
Sweden 0.14 0.05 0.03 0.01 
 
Figure 12. Estimated HCV- and HBV-related HCC mortality rate per 100 000 men and women by 
country 
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Table 4. Estimated HBsAg- and anti-HCV prevalence in cirrhosis patients by country 
Country 
Anti-HCV prevalence HBsAg prevalence 
% N References % N References 
Italy 61% 4125 56, 74 11% 4125 56, 74 
Spain 32% 451 75 10% 451 75 
Turkey 11% 505 66, 76 64% 731 66, 76 
 
Table 5. Estimated HCV- and HBV-related cirrhosis mortality rate by country 
Country 
HCV-related cirrhosis mortality 
(rate per 100 000 per year) 
HBV-related cirrhosis mortality 
(rate per 100 000 per year) 
 Men Women Men Women 
Italy 8.0 3.7 1.4 0.7 
Spain 3.7 1.1 1.1 0.3 
3.4 Screening for HBV and HCV infection 
Screening recommendations 
The information on national screening policies for HBV and HCV available from publications included in this study is 
limited. However, some policies were published and are generally similar in content, although some details differ 
significantly. 
General population. In France, two consensus conferences in 1997 and 1999 issued recommendations that 
urged healthcare professionals to systematically offer hepatitis C screening to the following patient groups: 
haemodialysis patients, patients with history of blood transfusion before 1991, drug users who either inject or sniff 
drugs, persons with history of incarceration, and healthcare professionals after occupational exposure to potentially 
infected blood, persons having unprotected sex with multiple partners, and persons living with an HCV-positive 
individual82,86. In Italy, a consensus conference in 2005 concluded that the following risk groups should be targeted 
for HCV screening: haemodialysis patients, subjects who received blood coagulation factors before 1987, subjects 
who received blood transfusions or an organ transplant before 1992, persons living with HCV-infected individuals, 
subjects with multiple sexual partners who have or have had a sexually transmitted disease87. 
Pregnant women. A recent conference showed that among a sample of seven countries, all had antenatal 
screening for HBsAg (G. Loeber, Dutch Conference on pre- and neonatal screening, April 2009). Only Ireland and 
Spain were reported to also screen for HCV. In the published literature, information was found on antenatal 
screening policies for four countries. Denmark introduced a policy of universal screening of pregnant women for 
HBsAg in 200577. In the United Kingdom, the Department of Health issued directives in 1987 and 1998 that all 
pregnant women should be offered HBsAg and HIV testing as an integral part of their antenatal care, by April 2000 
and January 2001, respectively78, 79. One review summarised the reasons for not screening for HCV during 
pregnancy in the United Kingdom80. Italy started antenatal screening for HBsAg in 198481. In France, pregnant 
women are not screened for HCV82.  
Blood donors. No publications were identified on national screening policies regarding screening for HBV or HCV 
in blood donors. However, information was obtained from a report for the Council of Europe (September 2009)28. 
This report states that in all 33 reporting member states, each donation is tested for HBsAg and anti-HCV. Anti-HBc 
testing is performed on all donations in 4 out of 33 (12%) reporting member states, and another five perform anti-
HBc testing for donations from first-time donors. EU Member States must follow the directives on blood safety 
given by the European Parliament and Council1
Migrants. No publications were identified on national screening policies regarding screening for HBV or HCV in 
migrants. 
 
 
                                                                    
1 Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of 
quality and safety for the collection, testing, processing, storage and distribution of human blood and blood 
components and amending Directive 2001/83/EC. 
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Drug users. In 1999, the United Kingdom recommended to increase the provision of testing for HBV among drug 
users83. Screening for HCV in IDUs has been supported by a range of professional consensus statements84. In the 
Netherlands, IDUs are targeted in an HBV screening and vaccination programme85. 
MSM. In the Netherlands, MSM (and other high-risk groups) are targeted for HBV screening as part of a 
vaccination programme for risk groups85. 
Effectiveness of screening 
Several studies reported process indicators of screening programmes such as coverage and the proportion of 
susceptible people which were vaccinated. These studies are listed below by target group of the screening. 
Similarly to information on screening policies, the numbers of studies captured was relatively limited. 
IDUs. The proportion of IDUs screened for HCV varied between 5% in the United Kingdom and 88% in Ireland88,89. 
One study from Hungary reported in 2004 that testing for HIV, HBV or HCV was not routinely offered at drug 
treatment centres. Where testing was provided, it was often unregulated and inconsistent. Furthermore, the same 
study suggested that results were not always communicated to the infected individual90. The proportion of 
susceptible IDUs that were completely vaccinated ranged from 56% in Ireland to 58% in the Netherlands (Table 6). 
Table 6. Overview of effectiveness studies of IDU screening for HBV and/or HCV 
Country 
Year  
of  
publication 
Condition Indicator Result Reference 
Hungary 2004 HBV and HCV Proportion of drug treatment centres offering screening See text 
90 
Ireland 2005 
HCV Proportion screened 88% 
89 HBV Proportion screened 68% 
HBV Proportion of susceptibles vaccinated 56% 
The 
Netherlands 2002 HBV 
Proportion screened 19% 85 
Proportion of susceptibles vaccinated 58% 
United 
Kingdom 2000 
HBV Proportion of drug agencies offering testing  27% 83 
HCV Proportion of drug agencies offering testing 24% 
United 
Kingdom 2008 HCV Proportion screened 5% 
88 
 
MSM. One study described the results of HBV screening of MSM in a genitourinary medicine (GUM) clinic in 
London, United Kingdom91. In this setting, 60% of MSM were screened for HBV and 47% of susceptibles 
completed vaccination. In an Amsterdam study, 64% of MSM were screened for HBV, and 74% of the susceptibles 
were vaccinated85.  
Contacts of HBsAg-positive individuals. A total of three studies on the screening of contacts of HBsAg positive 
individuals were published in Wales (United Kingdom), Naples (Italy) and Amsterdam (The Netherlands) 92,93,94. 
The Dutch study concerned contacts of HBsAg-positive women identified during antenatal screening. This study – 
the only one on the proportion of screened contacts – reported that 90% of all contacts were screened (1000 of 
1219). Of susceptible household contacts, 25%, 27% and 94% were vaccinated in Naples, Wales and the 
Netherlands, respectively.  
Pregnant women. Ten studies were published in 1990 on the screening of pregnant women for HBsAg (Table 7). 
The proportion of pregnant women screened for HBsAg ranged from 71% in a study from Italy to 100% in 2005. 
The proportion of vaccinated infants of HBV-infected mothers ranged from 85% in Italy to 100% (also in Italy; 
Table 7). 
High-risk individuals in the general population. One study was published on the uptake of the targeted HCV 
screening in the general population. This concerned a study from a region in France (Poitou-Charentes), where 3.7% 
of the population was tested in 2003102.  
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Table 7. Effectiveness studies of antenatal screening for HBsAg 
Country Year of publication 
Proportion 
screened (%) 
Proportion of infants completely vaccinated 
(%) Reference 
Denmark 2006 97% Not reported 77 
Greece 2006 91.3% Not reported 95 
Italy 1990 71% 85% 81 
Italy 1998 91.6% 100% 96 
Italy 2003 91.8% 95% 97 
Italy 2005 100% Not reported 98 
Switzerland 2004 99.3% 95% 99 
The Netherlands 2001 97% 99.7% 100 
United Kingdom 2002 93% Not reported 78 
United Kingdom 2004 99.9% 93% 101 
Economic analyses of screening for HBV and HCV 
A recent study details the cost-effectiveness of screening of migrants for chronic hepatitis B103. The study 
estimates that in the Netherlands, where no active screening is performed, only 4% of the eligible migrant 
population receives treatment. If case detection was improved through a screening programme targeted at 
migrants, approximately 15% of the population with active chronic hepatitis B would receive treatment, resulting in 
a 10% reduction in mortality. The estimated incremental cost-effectiveness ratio (ICER) of screening is around 
EUR 9 000 per quality-adjusted life year (QALY) gained, well below the value of EUR 20 000 per QALY gained that 
is commonly accepted as a threshold for considering the introduction of screening in the Netherlands.  
Seven economic analyses on screening of IDUs for HCV infection were identified104, 105, 106, 107, 108, 84, 82. However, 
two publications reported on the same economic analysis84, 108. Four of the six analyses were carried out in the UK 
and two in France (Table 8). All studies on screening IDUs, mostly conducted in the context of general practitioner 
practices, concluded that screening was likely to be cost-effective in terms of costs per QALY gained. 
Table 8. Economic analyses of screening IDUs in general practice 
Country ICER (year) Conclusion Comment Reference 
UK  Cost-effective 
Uncertainties regarding for 
example the uptake of 
screening remain. 
104 
 
UK GBP 28 120/QALY (2001) Cost-effective  
108, 84 
 
UK GBP 20 084/ LY (2004) GBP 16 514/QALY (2004) Cost-effective 
Case finding is most cost-
effective in people with 
longstanding infection 
105 
UK GBP 10 177/QALY (1997) Cost-effective  107 
France Not reported 
Screening IDUs and 
transfusion recipients was 
the most cost-effective 
 106 
France ICER compared to baseline is EUR 3 825 (1998) Cost-effective  
82 
 
HCV screening of GUM clinic attendees. The cost-effectiveness of universal HCV screening of GUM-clinic 
attendees was assessed in the United Kingdom108. This policy would probably not be cost effective, with a cost-
effectiveness ratio of GBP 84 570 per QALY (estimated with considerable uncertainty). 
HCV screening of prisoners. One economic analysis of screening and treatment for HCV in prisons was 
performed in England and Wales109. Screening would probably not be cost-effective, with an estimated cost per 
QALY of GBP 54 852. The authors concluded that the intervention would become more cost-effective if case-
finding costs were reduced and treatment acceptance and adherence enhanced. 
HBV screening of pregnant women. Three economic analyses were published on the screening of pregnant 
women for HBV110, 111, 112. Even though all studies were carried out in very low prevalence settings (United 
Kingdom and Belgium), they concluded that screening all women during pregnancy to prevent perinatal 
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transmission is highly cost-effective. The ICERs were GBP 2 437 and GBP 2 500 per life year gained (LYG) in the 
UK, and BEF 583 581 per LYG in Belgium112,110, 111. 
One study compared the cost-effectiveness of HBV NAT testing of blood donors to assay testing113. The authors 
concluded that HBV NAT testing of blood donors was not cost-effective when compared to testing with assays.  
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4 Discussion and conclusion 
This literature review aims to provide facts and evidence that can be used to inform policy making on primary and 
secondary prevention of HBV and HCV. It attempts to achieve this goal by assessing published information on the 
burden of HBV- and HCV-related infection and disease in EU/EEA countries, and by summarising existing HBV and 
HCV screening policies and their effectiveness. This review is not intended to draw a complete picture of the 
situation in Europe, nor is it intended to form the single basis for decisions on prevention efforts. Rather, it is part 
of a series of ECDC-produced reports that each provide concise information on a specific area, for the benefit of 
decision-makers at both the EU and national levels.  
The conclusions presented in the report should be seen in the context of the collected data. 
4.1 The prevalence of HBV and HCV in the general 
population  
Based on an analysis of the data extracted from the literature we reviewed for this study, the prevalence of HBV 
infection in the general population varies widely between EU/EFTA/EU candidate countries, ranging from 0.1% in 
Ireland and the Netherlands to more than 7% in the eastern part of Turkey. Countries in the central or southern 
part of the EU and its associated and candidate countries (e.g. Turkey, Romania, Bulgaria and Greece) have a 
higher prevalence than countries in the northern or western part of the EU. Unfortunately, data on the HBV-related 
burden of disease and mortality was not available for the countries with the highest prevalence.  
Based on prevalence surveys, the prevalence of HBV in the general population is likely to be considerably 
underestimated in low-prevalence countries, as high-risk groups are often not adequately represented in the 
studies. As an illustration of this, data from the Netherlands and Ireland show that the estimated number of 
infected migrants is higher than the estimated total number of infected individuals in the general population, 
probably because migrants are underrepresented in the final population samples for HBV prevalence surveys. 
Although the prevalence in blood donors can be used as a proxy for the prevalence in the general population, 
blood donors are not a representative sample of the general population, due to their pre-selection. The prevalence 
in first-time blood donors can generally be regarded as the lower limit of the prevalence in the general population, 
except for countries where donors are remunerated. This is consistent with the finding that the prevalence 
estimates in first-time blood donors for both HBV and HCV were lower than those for the general population (with 
the exception of Cyprus for HBV). By contrast, in nearly all countries where data was available, pregnant women 
had a considerably higher prevalence when compared with the general population. The only exception is Spain, 
where the HBV prevalence estimate for pregnant women (only available for Catalonia) showed a lower prevalence 
than estimated for the general population (0.1 and 1.0%, respectively). Most likely this reflects the impact of the 
adolescent HBV vaccination programme implemented in this region since 1990. 
The prevalence of HCV in the general population varies widely across countries, with ranges from 0.4% in Sweden, 
Germany and the Netherlands to over 20% in one region of Italy. In general, countries in the southern part have a 
higher HCV prevalence compared to countries in the north or west of the EU. Italy in particular has a high general 
population prevalence of HCV, much higher than the country’s estimated HBV prevalence. Epidemiologic and 
phylogenetic assessments suggest this is caused by a period of increased iatrogenic transmission that took place 
around the 1950s39, 40, 114.  
Five groups of countries can be distinguished (Table 9) when comparing the prevalence estimates for HBV and 
HCV in the general population (or in pregnant women if no general population estimate was available). Table 9 
assigns countries with available data in one of three prevalence groups – low (≤1%), medium (>1% and ≤2%) 
and high (>2%)2
• Romania has a high prevalence of both HBV and HCV.  
.  
• Greece and Turkey have a high HBV prevalence and a medium HCV prevalence.  
• Italy has a high HCV prevalence and a medium HBV prevalence.  
 
                                                                    
2 Arbitrary classification only used for the purpose of illustration. 
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• France and Spain have a medium HCV prevalence and a low HBV prevalence.  
• Seven countries (Belgium, Germany, Netherlands, Slovakia, Sweden, Switzerland** and the United Kingdom) 
have a low prevalence for both HBV and HCV. 
The remaining 21 countries have insufficient data for HBV (Bulgaria, Poland), HCV (Cyprus, Czech Republic, 
Denmark, Finland, Ireland) or both HBV and HCV (Austria, Croatia, Estonia, the former Yugoslav Republic of 
Macedonia, Hungary, Iceland, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Norway, Portugal, Slovenia).  
 
Among countries with available data, Italy has by far the largest number of HCV infected individuals; Turkey has 
the largest number of HBV-infected individuals.  
 
Table 9. Classification of countries according to prevalence estimates and availability of data 
HBsAg 
 
HCV Ab 
Low (≤1%) Medium (>1% and 
≤2%) 
High 
(>2%) 
Insufficient data 
Low (≤1%) BE, CH, DE, NL, SK, 
SE, UK 
   
(>1% and 
≤2%) 
FR, ES  GR, TR BU, PL 
High (>2%)  IT RO  
Insufficient 
data 
CY, CZ, DK, FI, IE   AT, CR, EE, FYROM, HU, IS, LV, LI, LT, LU, 
MT, NO, PT, SL 
4.2 The prevalence of HBV and HCV in high-risk groups 
The number of HBV and/or HCV prevalence studies on migrants is limited. Available data show that in nearly all 
countries and ethnic groups the estimated prevalence of both HBV and HCV is higher among migrants compared to 
the general population. The only exception is HCV in Italy, where the estimated general population prevalence is 
higher than that estimated in migrant groups. The estimates of the number of migrants infected with HBV and HCV 
show that some countries (including Germany, Spain, France, Italy, and the United Kingdom) have large numbers 
of migrants with HBV and/or HCV infection.  
A large number of studies is available on estimated HCV prevalence in IDUs. Even though the representativeness 
of studied populations is variable, most studies suggest that HCV infection is highly prevalent among IDUs in 
Europe. In the literature reviewed for this study, the prevalence of HBV among IDUs was in most cases reported to 
be much lower than that of HCV. 
4.3 Screening policies and effectiveness 
There is surprisingly little data on HBV and/or HCV screening policies for high-risk groups or the general population. 
Where recommendations were found, e.g. on general population screening for HCV in France and Italy, these were 
based on consensus conferences. It is likely that more written policies or guidance documents exist in national 
languages in the format of reports and other national documentation. However, a review of such literature was 
outside the scope and capacity of this study. 
Antenatal screening for HBV with subsequent vaccination of infants born to HBsAg-positive mothers is an important 
intervention to control HBV, as perinatal transmission of HBV is efficient and usually leads to chronic infection in 
the infant. This is supported by an economic analysis which shows that universal antenatal HBV screening is highly 
cost-effective. Nevertheless, data or formal assessments on the effectiveness of antenatal HBV screening were 
lacking for most countries. It is likely that evaluations of programmes for prevention of perinatal HBV infection are 
generally not published in the scientific literature. For those countries where data were available, screening 
appears to be well implemented, with participation rates of 90% and more in all countries. Reported vaccination 
coverage of infants born to HBsAg-positive mothers was more than 95%. (ECDC comment: more information on 
this can be found in a series of reports produced by the ECDC-commissioned VENICE project.) No study was 
available on the follow-up, e.g. whether HBsAg-positive mothers were referred to healthcare. As new treatment 
options are available for HBV and HCV, access and attachment to treatment is an important indicator for the 
evaluation of screening programmes. 
 
                                                                    
** The HBV general population prevalence for Switzerland was considered low, based on the prevalence of 1.2% in 
pregnant women and the prevalence of 0.14% in blood donors. 
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The review shows that in many countries in Europe migrants have a higher prevalence of HBV and HCV than the 
rest of the general population. This implies that they will also be disproportionally affected by the burden of 
disease due to HBV and HCV. Screening with subsequent access to treatment could prevent some of the disease 
burden115. However, this review shows that the evidence base for this cannot be completely evaluated as almost 
no studies exist on the effectiveness or cost-effectiveness of migrant screening for HBV and/or HCV in Europe. 
Evidence from the US suggests that screening migrants for chronic HBV is cost-effective20. The first study in 
Europe, conducted in the Netherlands, suggests that screening and early treatment of migrants for chronic HBV is 
cost-effective103. 
Limited data were available on the effectiveness of screening for MSM. The only two available studies were carried 
out during an HBV vaccination campaign for MSM. Considering the recently reported increase in HCV among MSM, 
more information on the effectiveness of screening is needed44. 
The evidence base for the screening of IDUs is somewhat better developed. Economic analyses of drug user 
screening for HCV in France and the United Kingdom suggest that this is a cost-effective intervention. Despite this, 
limited data suggest that the implementation of this policy is highly variable, with uptake ranging from 88% in 
Ireland to 5% in the UK. Low uptake can be explained by the fact that in several countries HCV screening is not 
routinely offered in drug treatment centres. No economic analyses of screening of IDUs for HBV were available in 
the publications reviewed for this study.  
The information captured in this review shows that screening of blood donors for signs of HBV- and HCV-infection 
is common practice in all countries of the region.  
4.4 Limitations  
While a serious attempt was made to design the study in order to capture the most relevant information, it still has 
several limitations. To better reflect recent developments, this review was limited to studies published since 2000, 
which potentially excludes relevant data published earlier. This might partly explain the limited number of 
publications identified on antenatal screening policies. As antenatal screening programmes were uniformly 
implemented in the countries of the region during the last decades of the 20th century, studies reporting on this 
topic were probably published before 2000.  
Also, a search of literature databases containing mainly scientific studies is probably not adequate when it comes 
to identify existing screening policies. To compensate for these shortcomings, this aspect has been included in 
various surveys in Member States on surveillance and prevention with respect to hepatitis B and C, conducted by 
ECDC or through the EUVACNET and VENICE networks.  
The different ranges covered by the various studies, in combination with the differences in mean age of study 
participants, make it difficult to compare the prevalence estimates across countries. Although studies that covered 
only children were excluded, the difference in age of the participants still limits the validity of comparisons between 
prevalence estimates. For many prevalence estimates, the mean age of the population was not included, which 
made it impossible to calculate prevalence by birth cohort. 
Trends over time in the burden of HBV and/or HCV infection were not covered, nor was the impact of vaccination.  
Another major limitation of the study was its sole concentration on publications issued in English. This leads to a 
bias in favour of inclusion of studies from countries where English is the native language or where there is a strong 
tradition of publishing in English. It is almost inevitable that this results in major omissions of both data and bodies 
of evidence from several large countries/language groups. 
4.5 Conclusions 
Our review demonstrated the diversity in the burden of infection and disease due to HBV and HCV, but also in the 
availability of data across 34 countries in Europe. Data on general population prevalence of these infections were 
lacking for most of the countries studied. Of those countries with information based on general population studies, 
some have evidence of low general population prevalence of both HBV and HCV, but with a high burden in high-
risk groups, the most numerous of which may be migrants. Other countries have mixed patterns of HBV and HCV 
endemicity. Especially for HCV infection, IDUs are still a significant group at risk, with high prevalence rates 
reported from most countries. Even though the information available is far from complete, neither in detail nor in 
coverage, some general patterns and conclusions can be drawn. The most significant finding is that there is 
evidence for significant disease burden caused by both HBV and HCV infection in many, if not most, countries in 
the EU and its neighbourhood.  
It is likely that considerable health gain can be achieved by secondary prevention of HBV and HCV, including early 
detection through screening and treatment of identified chronically infected patients when indicated. We found 
indeed evidence that HCV screening of IDUs is cost-effective. The evidence-base for HBV screening of migrants is 
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insufficiently studied, but the one study published on this topic suggests that this intervention is cost-effective. 
Formally collected evidence for HBV and/or HCV screening of other high-risk groups or the general population is 
still lacking, as such studies or evaluations have not been performed. As part of a comprehensive prevention and 
control policy – including other effective measures and direct links to guaranteed access to effective treatment – 
wider screening could provide opportunities for significant future savings in both healthcare costs and productivity 
gains. 
Better surveillance and monitoring activities, further research, and realistic studies on costs are needed to provide 
the information basis for rational policy making on future secondary prevention of HBV and HCV infection in the EU 
and its neighbourhood.  
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Annex 1. Tables 
Table A1. Prevalence of HBsAg in the general population 
Reference Country Period Area Region Sampling N % (95% CI) Remarks 
31 Belgium 2002-2003 nationwide   residual 1 496 0.7   Children only 
116* Belgium 2003 regional Flanders random 1 834 0.7 (0.5-0.8) Oral fluid  
33* Cyprus 2006 regional North random 585 0.9 (0.2-2.0) Age range 1-30 years 
117* Czech Republic 2001 nationwide   random 2 658 0.6    Standardised prevalence 
118 Denmark 1994-1995 nationwide   convenience 2 428 0.1   Children only 
31* Finland 1997-1998 nationwide   residual 3 083 0.2     
119* Germany 1993-1996 nationwide   random 5 305 0.6 (0.4-0.8)   
120 Germany 1997-2001 regional North East random 4 310 0.4     
121* Germany 1998 nationwide   random 6 748 0.6 (0.4-0.8)   
122* Greece 1997-1998 regional Peloponnesus random 1 500 2.1 (1.5-3.0)   
123 Greece 2002 regional Athens convenience 98 0.0   Children only 
124 Greece 2003-2004 nationwide   random 1 286 0.6 (0.3-1.3) Children only 
31* Ireland 2003 nationwide   residual 2 535 0.1     
31* Italy 1996 nationwide   residual 3 522 0.6     
38* Italy 2002 regional North convenience 956 1.0     
125* Italy 1997 regional Central random 250 1.2     
126* Italy   regional South random 488 0.2     
127* Italy 2002-2003 regional South random 1 645 1.8 (0.4-1.2)   
128 Italy 2003-2006 regional South random 4 496 2.5  Standardised prevalence 
129* Italy 1994-1994 regional Sardinia convenience 3 324 4.3     
130* Italy 1999-2000 regional Sicily random 721 0.7     
31* Netherlands 1995-1996 nationwide   random 6 750 0.1     
131 Netherlands 2004 regional Amsterdam random 1 364 0.4 (0.1-0.7) Standardised prevalence 
31* Romania 2002 nationwide   residual 1 259 5.6     
31* Slovakia 2002 nationwide   random 3 569 0.6     
132* Spain 1996 regional Catalonia random 2 142 1.2 (0.7-1.7) Standardised prevalence 
36* Spain 2002 regional Catalonia random 2 620 0.7 (0.4-1.0)   
133* Sweden 1991-1994 regional Malmö random 5 533 0.2     
134 Turkey 1998 nationwide   random 2 683 5.4   Age range 0-30 years 
135* Turkey 2006-2007 regional West random 2 852 2.5     
136 Turkey 1998 regional West random 717 1.7   Children only 
137* Turkey 2002-2004 regional Central convenience 1 320 6.6     
138* Turkey 1996 regional Central convenience 571 6.7     
139* Turkey   regional Central random 1 095 5.5     
140* Turkey 1997-1999 regional East convenience 400 9.0   32 year olds 
141 Turkey   regional East random 802 2.7   Children only 
142 Turkey   regional East random 1 091 1.8   Children only 
143* Turkey 2003 regional East random 2 888 7.0     
* Included in general population prevalence estimate presented in Figure 3.  
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Table A2. Prevalence of anti-HCV in the general population 
Refer- 
ence Country Period Area Region Sampling N % (95% CI) Remarks 
116* Belgium 2003 regional Flanders random 1 834 0.1 (0.1-0.4) Oral fluid 
144* Belgium 1993-1994 regional Flanders random 4 055 0.9 (0.5-1.1)   
145* Bulgaria 1999-2000 regional South Central convenience 2 211 1.3 (1.2-1.4) Standardised prevalence 
117* Czech Republic 2001 nationwide   random 2 658 0.2     
146* France 1997 regional South convenience 11 804 1.3 (1.1-1.5)   
121* Germany 1998 nationwide   random 6 748 0.4 (0.2-0.5)   
120 Germany 1997-2001 regional North East random 4 310 0.5     
123 Greece 2002 regional Athens convenience 216 0.0   Children only 
122* Greece 1997-1998 regional Peloponnesus random 1 500 0.5 (0.2-1.1)   
147* Greece 1997 regional Zakinthos  (Island) random 718 1.3     
148 Italy 1996-1997 nationwide   residual 3 577 2.7 (2.2-3.2)   
38* Italy 2002 regional North convenience 956 2.6     
40* Italy 1994-1995 regional North convenience 2 154 3.3 (2.6-4.1)   
149* Italy   regional North  convenience 4 820 2.4 (2.0-2.8)  
39* Italy   regional North random 496 11.5   Elderly >65 years 
150 Italy 1983-1987 regional Central random 3 884 1.8     
151* Italy   regional Central convenience 300 16.3 (12.0-20.6)   
125* Italy 1997 regional Central random 250 22.4 (20.8-24.1)   
126* Italy   regional South random 488 16.2     
152* Italy 2000-2002 regional South convenience 2 753 7.9     
127* Italy 2002-2003 regional South random 1 645 6.5 (5.3-7.7)   
128 Italy 2003-2006 regional South random 4 496 6.7  Standardised prevalence 
129* Italy 1994-1995 regional Sardinia convenience 3 324 3.2     
130* Italy 1999-2000 regional Sicily random 721 10.4     
131* Netherlands 2004 regional Amsterdam random 1 364 0.6 (0.1-1.1) Standardised prevalence 
153* Netherlands 2006 regional East convenience 2 200 0.2     
154* Poland 1999 regional North convenience 2 561 1.9     
155* Romania 2006-2008 nationwide   random 8 039 3.5 (3.1-3.9)   
156* Spain 1996 regional Catalonia random 2 142 2.5 (1.8-3.2) Standardised prevalence 
157* Spain 1997-1998 regional North random 1 170 1.6 (1.0-2.6)   
133* Sweden 1991-1994 regional Malmö random 5 533 0.4     
135* Turkey 2006-2007 regional South West random 2 852 1.0     
137* Turkey 2002-2004 regional Central convenience 1 320 2.2     
139* Turkey   regional Central random 1 095 2.1     
37* United Kingdom 1996 regional England and Wales residual 6 401 0.7     
* Included in general population prevalence estimate presented in Figure 4.  
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Table A3. Prevalence of HBsAg in first-time blood donors 
Reference Country Period  Area Region N % 95% CI 
28* Belgium 2005     0.06  
28* Bulgaria 2005     5.2  
28* Croatia 2005     0.2  
32* Cyprus     regional North 5 057 3.0   
28* Czech Republic 2005     0.07  
28* Finland 2005     0.04  
28* France 2005     0.1  
28 Germany 2005     0.1  
158* Germany 1997 2002 nationwide   2 919 442 0.2  
159 Germany     not specified   14 251 0.1  
28 Greece 2005     3.0  
34* Greece 1995 1997 regional North West, Epirus 6 696 0.9 0.6-1.1 
28* Hungary 2005     0.00  
28* Ireland 2005     0.02  
160* Italy 2005   regional North West, Piedmont 6 313 0.4  
161* Lithuania 2005 2006 regional Vilnius 24 880 1.7  
28* Luxembourg 2005     0.1  
28* Netherlands 2005     0.09  
28* Norway 2005     0.02  
162* Poland 1998 2000 regional North East 22 618 0.9  
28* Romania 2005     4.3  
28* Slovakia 2005     0.2  
28* Slovenia 2005     0.09  
28* Spain 2005     0.1  
28* Sweden 2005     0.06  
28* Switzerland 2005     0.1  
28* United Kingdom 2005     0.04  
* Included in first-time blood donor population prevalence estimate presented in Figure 4.  
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Table A4. Prevalence of anti-HCV in first-time blood donors 
Reference Country Period  Area Region N % 95% CI 
28* Belgium 2005     0.06  
28* Bulgaria 2005     0.9  
28* Croatia 2005     0.06  
32* Cyprus 2005   regional North 5 057 0.5  
28* Czech Republic 2005     0.1  
28* Finland 2005     0.04  
28* France 2005     0.06  
28 Germany 2005     0.08  
158* Germany 1997 2002 nationwide   2 919 442 0.1  
28* Greece 2005     0.6  
28* Hungary 2005     0.3  
28* Ireland 2005     0.02  
161* Lithuania 2005 2006 regional Vilnius 24 894 1.7  
28* Luxembourg 2005     0.06  
28* Netherlands 2005     0.03  
28* Norway 2005     0.06  
162* Poland 1998 2000 regional north east 22 618 0.6  
28* Romania 2005     3.3  
28* Slovakia 2005     0.06  
28* Slovenia 2005     0.02  
28 Spain 2005     0.1  
163* Spain 1999 2001 nationwide   216 590 0.2  
28* Sweden 2005     0.1  
28* Switzerland 2005     0.08  
28* United Kingdom 2005     0.04  
* Included in blood donor population prevalence estimate presented in Figure 4.  
Table A5. Prevalence of HBsAg in pregnant women 
Reference country Period  Area Region N % 95% CI 
77* Denmark 2005 2006 nationwide   29 708 0.3   
164 Denmark 2000 2001 regional Copenhagen 4 094 0.4 0.3-0.7 
165* France 1984 1998 regional Limoges 22 859 0.7   
166* Germany 1996 2005 regional Heidelberg 5 518 1.6   
167 Greece 2008 2008 regional Athens 749 4.1   
168 Greece 1994 2002 regional Athens (Piraeus) 5 497 3.9   
95* Greece 2003   nationwide   3 384 2.9 2.3-3.4 
169* Ireland 1998 2000 regional Dublin 16 222 0.4   
97* Italy 2001   nationwide   10 881 1.7 1.4-1.9 
170 Italy 1996   regional North, Padua 2 059 1.0   
98 Italy 2001 2003 regional Sicily, Palermo 3 318 1.1   
100* Netherlands 1993 1998 regional Amsterdam 56 756 1.2   
171* Slovakia 2000 2004 regional Bratislava 90 4.4   
35* Spain 2004   regional Catalonia 1 534 0.1 0.0-0.3 
99* Switzerland 2001   regional Basel 1 503 1.2 0.7-1.8 
172* United Kingdom 2002   regional London 110 621 1.0   
* Included in antenatal population prevalence estimate presented in Figure 5.  
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Table A6. Prevalence of anti-HCV in pregnant women 
Reference country Period  Area Region N % 95% CI remarks 
173* Germany 1992 1996 regional Munich 3 712 0.9     
168* Greece 1994 2002 regional Athens (Piraeus) 5 497 0.8     
174* Greece 1996 1997 regional North 2 408 2.0     
175 Italy 1996 1999 regional North 5 840 1.8   
170* Italy 1996   regional North 2 059 1.9     
176* Italy 1995 1998 regional North 15 250 2.4     
177* Italy 1996 2001 regional North 13 025 0.8     
171* Slovakia 2000 2004 regional Bratislava 90 0.0     
178* Switzerland 1990 1991 nationwide   9 057 0.7     
179* United Kingdom 1997 1998 
nationwide
*   126 009 0.2 0.1-0.3 
neonatal dried blood spots, 
prevalence extrapolated to UK 
180* United Kingdom 1996   regional 
Northern 
and 
Yorkshire 
16 675 0.2 0.1-0.3 adjusted for sampling procedure 
180* United Kingdom 1996   regional London 25 940 0.4 0.3-0.5 
adjusted for sampling 
procedure 
181* United Kingdom 1997 1999 regional London 4 729 0.8 0.6-1.0   
182* United Kingdom 1997   regional Scotland 3 548 0.6 0.4-1.0   
183* United Kingdom 2000   regional Scotland 30 259 0.3   neonatal dried blood spots 
* Included in antenatal population prevalence estimate presented in Figure 5.  
Table A7. Prevalence of HBsAg in migrants ethnic minorities, Europe 
Reference Country Study period Country of birth/ ethnicity Status N 
HBsAg 
prevalence 
(%) 
Remark 
184 Greece not reported Albania Refugees 130 15.4  
185 Italy 1997 Albania Refugees 670 13.6  
186 Italy 2005-2006 South America Refugees 130 10.7  
187 Italy 2005 Africa, Asia Refugees 556 10.7  
188 Italy 2005 Sub-Sahara Africa Illegal immigrants 182 9.3  
189 Italy 2003-2004 Several countries Refugees 890 9.3  
190 Spain 2001-2004 Several countries Residents 1 905 7.7  
46 Italy* 2000 Turkey (Kurds) Refugees 368 6.8  
191 United Kingdom 2000 Somalia Residents 448 5.7  
123 Greece 2002 Roma Residents 118 4.2 Children only 
192 Italy 1999 Kosovo Refugees 526 2.9  
46 Italy* 2000 Iraq (Kurds) Refugees 637 2.2  
193 Netherlands 2004 Several countries Residents 205 1.0  
* One publication on two migrant groups 
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Table A8. Prevalence of anti-HCV in migrants/ethnic minorities, Europe 
Reference Country Study period Country of birth/ ethnicity Status N 
anti-HCV 
prevalence 
(%) 
Remark 
48 Hungary 2004 Roma Residents 64 23.4  
190 Spain 2001-2004 Several countries Residents 1 848 3.1  
184 Greece not reported Albania Refugees 130 2.3  
188 Italy 2004-2005 Sub-Saharan Africa Illegal immigrants 182 2.2  
193 Netherlands 2004 Several countries Residents 205 1.5  
194 Italy 2002-2006 Several countries Residents 120 0.8 Children only 
192 Italy 1999 Kosovo Refugees 526 0.7  
185 Italy 1997 Albania Refugees 670 0.3  
46 Italy* 2000 Turkey (Kurds) Refugees 368 0.1  
123 Greece 2002 Roma Residents 216 0.0 Children only 
46 Italy* 2000 Iraq (Kurds) Refugees 637 0.0  
 
Table A9. Prevalence of HBsAg in IDUs, 1991-2006. Adapted from table INF 114, EMCDDA 
Country Period Area Region N HBsAg prevalence (%) 
Belgium 2007 regional Antwerp 307 2.6 
Belgium 2007 regional Flanders 45 0 
Bulgaria 2006 national  614 11.6 
Bulgaria 2007 regional Sofia 656 5.6 
Germany 1999 regional Munich 140 2 
Ireland 2003 regional Dublin 63 0 
Greece 2006 national  1 293 3.6 
Greece 2006 national  757 1.7 
Cyprus 2007 national  102 7.8 
Lithuania 2006 regional Vilnius 246 8.9 
Lithuania 2006 regional Vilnius 422 3.3 
Luxembourg 2005 national  255 3.9 
Hungary 2007 national  564 0.4 
Netherlands 2000 regional The Hague 199 3 
Poland 2005 regional Lubelski 87 1.2 
Poland 2005 regional Warminsko-mazurskie 82 8.5 
Poland 2005 regional Warsaw 178 7.3 
Portugal 2007 national  1 395 2.9 
Portugal 2007 national  877 3.2 
Portugal 2007 national  4 267 6.9 
Romania 2007 regional Bucharest 113 11.5 
Slovenia 2002 national  564 3.4 
Croatia 2007 national  200 0.5 
Norway 2007 regional Oslo 222 0.5 
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Table A10. Estimated number of individuals in the general population and in the largest three 
migrant groups who are positive for HBsAg and/or anti-HCV, by country 
Country 
Total 
population 
size 
(number) 
HBsAg 
prevalence 
in the 
general 
population 
(%) 
anti-HCV 
prevalence 
in the 
general 
population 
(%) 
HBsAg 
positive 
individuals 
(number) 
Anti-HCV 
positive 
individuals 
(number) 
Migrants, 
three 
largest 
groups 
(number) 
HBsAg 
positive 
migrants 
(number) 
Anti-HCV 
positive 
migrants 
(number) 
Austria 8 355 260     461 100 18 444  
Belgium 10 754 528 0.7% 0.6% 75 282 64 527 365 126 14 605 9 512 
Bulgaria 7 606 551  1.3%  98 885    
Croatia 4 435 056        
Cyprus 793 963 0.9%  7 146     
Czech Republic 10 467 542 0.6%  62 805     
Denmark 5 511 451     69 342 2 774  
Estonia 1 340 415        
Finland 5 326 314 0.2%  10 653  52 397 2 412  
France 64 351 000  1.3%  836 563 1 871 000 74 840 23 290 
Germany 82 050 000 0.6% 0.4% 492 300 328 200 2 626 700 105 068 60 839 
Greece 11 257 285 2.1% 1.0% 236 403 112 573 553 093 22 124 14 718 
Hungary 10 031 208     226 436 19 283  
Iceland 319 368     3 580 241  
Ireland 4 465 540 0.1%  4 466  103 394 5 115  
Italy 60 053 442 1.4% 5.2% 840 748 3 122 779 1 061 375 62 987 27 031 
Latvia 2 261 294     296 816 11 873 5 199 
Liechtenstein 35 590        
Lithuania 3 349 872     174 879 6 995 2 993 
Luxembourg 493 500     60 412 2 416  
Macedonia 2 048 620        
Malta 413 627        
Netherlands 16 486 587 0.1% 0.4% 16 487 65 946 551 155 22 046 15 106 
Norway 4 799 252     51 166 2 047 808 
Poland 38 135 876  1.9%  724 582 497 353 19 894  
Portugal 10 627 250     300 118 27 018 4 636 
Romania 21 498 616 5.6% 3.5% 1 203 922 752 452 72 179 6 423 2 310 
Slovakia 5 412 254 0.6%  32 474  26 285 1 051  
Slovenia 2 032 362     164 222 6 569 412 
Spain 45 828 172 1.0% 2.0% 458 282 916 563 1 566 951 93 337 27 761 
Sweden 9 256 347 0.2% 0.4% 18 513 37 025 212 245 8 490  
Switzerland 7 700 202     493 718 19 749  
Turkey 71 517 100 5.2% 1.5% 3 718 889 1 072 757 593 999 52 609 6 535 
United Kingdom 61 634 599  0.7%  431 442 1 073 000 42 920 21 187 
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Table A11. Estimated HCC mortality rate for males and females by country 
Country Year Rate per  100 000 men 
Rate per  
100 000 women Reference 
Austria 2000-2004 4.24 0.92 50 
Belgium 1990-1996 2.35 1.69 51 
Bulgaria 1990 8.03 5.35 51 
Czech Republic 1989 2.76 0.99 50 
Denmark 2001 1.49 0.41 50 
Estonia 1999 5.36 2.26 50 
Finland 2000-2004 2.69 0.91 50 
France 2003 6.79 0.96 50 
Germany 2000-2004 2.89 0.75 50 
Greece 2000-2004 1.55 0.3 50 
Hungary 2003 7.72 2.92 50 
Ireland 2000-2004 0.78 0.3 50 
Italy 2002 6.72 1.92 50 
Latvia 1999 5.09 1.87 50 
Lithuania 1999 1.40 0.39 50 
Netherlands 2000-2004 1.05 0.33 50 
Poland 2000-2004 4.15 2.65 50 
Portugal 2003 2.71 0.68 50 
Spain 2000-2004 4.92 1.53 50 
Sweden 2000-2002 0.68 0.27 50 
United Kingdom 2000-2004 1.38 0.36 50 
Norway 1986-1989 0.96 0.43 50 
Switzerland 2000-2004 5.93 1.75 50 
Reference 50: Bosseti, 2008 
Reference 51: La Vecchia, 2000 
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Table A12. Estimated cirrhosis mortality rate for males and females by country 
Country Year Rate per  100 000 men 
Rate per  
100 000 women 
Austria 2000-2002 20.72 7.13 
Belgium 1995-1996 10.44 5.42 
Bulgaria 2000-2002 19.44 4.57 
Czech Republic 2000-2002 18.02 9.28 
Denmark 2000-2001 14.96 6.04 
Estonia 2000-2002 22.4 10.55 
Finland 2000-2002 13.58 4.93 
France 2000-2002 14.45 5.4 
Germany 2000-2002 18.2 7.38 
Greece 2000-2002 5.45 1.48 
Hungary 2000-2002 68.27 20.91 
Ireland 2000-2002 4.77 5.64 
Italy 2000-2002 13.01 5.97 
Latvia 2000-2002 15.07 6.87 
Lithuania 2000-2002 20.14 8.15 
Luxembourg 2000-2002 17.45 7.51 
Malta 2000-2002 4.87 1.02 
Netherlands 2000-2002 4.4 2.33 
Poland 2000-2002 15.86 4.91 
Portugal 2000-2002 18.39 5.48 
Romania 2000-2002 48.47 22.55 
Slovakia 2000-2002 31.01 9.72 
Slovenia 2000-2002 35.03 13.26 
Spain 2000-2002 11.75 3.55 
Sweden 2000-2002 4.99 2.46 
Norway 2000-2002 4.52 2.22 
Source: Bosetti, 2007 (reference 49) 
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Annex 2. Search strategies 
1 Search strategy review question 1 
What is the prevalence of chronic HBV and HCV infection* in each of the 34** countries  
• in the general population? 
• in the following groups:  
− blood donors; 
− pregnant women; 
− drug users (DUs); 
− men having sex with men (MSM); 
− migrants? 
* Defined as HBsAg- and HCV-RNA-positive or anti-HCV-positive individuals, respectively. 
** All 27 EU Member States, EEA/EFTA (Norway, Iceland, Liechtenstein and Switzerland) and candidate countries 
(Croatia, the former Yugoslav Republic of Macedonia and Turkey) (n=34). 
Search strategy Q1a 
The infection: hepatitis B or hepatitis C 
1 hepatitis B 
2 Hepatitis B, chronic (MeSH) 
3 Hepatitis C (MeSH) 
4 HBV 
5 HCV  
6 or 1–5 
 
The outcome: prevalence 
7 Prevalence (MeSH) 
8 seroprevalence 
9 Seroepidemiologic Studies (MeSH) 
10 Seroepidemiolog$ 
11 Serologic$ markers 
12 Serology 
13 HBsAg 
14 HBs Ag 
15 Hepatitis B Surface Antigens (MeSH) 
16 Hepatitis B Surface Antigen$ 
17 Anti-HCV 
18 Hepatitis C Antibodies (MeSH) 
19 HCV-RNA 
20 Carrier state (MeSH) 
21 Carrier 
22 or 7–21 
 
The population: general population 
23 population 
24 community 
25 child$ 
26 adolesc$ 
27 adults$ 
28 elder$ 
29 residual sera 
30 Population Surveillance (MeSH) 
31 survey 
32 surveillance 
33 or 23-32 
 
The population: countries 
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34 see country list 
35 EU 
36 European Union 
37 Europe 
38 or 34–37 
 
39 and 6, 22, 33, 38 
Search strategy Q1b 
The infection: hepatitis B or hepatitis C 
40 = Question 1: row 6 
 
The outcome: prevalence 
41 = Question 1: row 22 
 
The Population: specific groups 
42 Blood donors (MeSH) 
43 blood-donor population 
44 IDU  
45 Drug users (MeSH) 
46 Substance Abuse, Intravenous (MeSH) 
47 Substance abuse$ 
48 MSM  
49 men adj2 sex adj1 men (men having sex with men/men who have sex with men) 
50 Homosexuality, Male (MeSH) 
51 homosex$ 
52 homo adj3 $sexual 
53 Gay men 
54 Migrant$  
55 Transients and Migrants (MeSH) 
56 Immigrant$ 
57 Emigrants and Immigrants (MeSH) 
58 Minorit$ 
59 Minority Groups (MeSH) 
60 Pregnan$ 
61 Pregnancy (MeSH) 
62 Antenatal 
63 Prenatal 
64 or 42-63 
 
The population: countries 
65 = Question 1: row 38 
 
66 and 40, 41, 64, 65 
2 Search strategy review question 3 
What is the burden of HBV and HCV related cirrhosis and hepatocellular carcinoma (HCC) in each of the 34 
countries*? 
• What is the burden (morbidity and mortality) due to cirrhosis and HCC in each of the 34 countries*? 
• What is the proportion of the burden of cirrhosis and HCC that is attributable to chronic HBV and HCV 
infection in each of the 34 countries*? This will be assessed by estimating the prevalence of HBsAg and 
HCV-RNA in cases of cirrhosis and HCC, a method that has recently been used by Perz et al.30.  
* All 27 EU Member States, EEA/EFTA (Norway, Iceland, Liechtenstein and Switzerland) and candidate countries 
(Croatia, the former Yugoslav Republic of Macedonia, and Turkey) (n=34). 
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Search strategy Q3a 
Disease: cirrhosis and HCC 
1 Cirrho$ 
2 liver cirrhosis (MeSH) 
3 hepatocellular carcinoma (MeSH) 
4 HCC 
5 liver cancer 
6 or 1-5 
 
Outcome: burden of disease 
7 morbidity (MeSH) 
8 prevalence (MeSH) → under MeSH ‘morbidity’ 
9 incidence (MeSH) → under MeSH ‘morbidity’ 
10 burden of disease 
11 QALY 
12 DALY 
13 mortality 
14 death 
15 or 7-14 
 
Population: countries 
16 = Question 1: row 38 
 
17 and6, 15, 16 
Search strategy Q3b 
The infection: hepatitis B or hepatitis C 
18 = Question 1: row 6 
 
The outcome: prevalence 
19 = Question 1: row 22 
 
The population: patients with cirrhosis or HCC 
20 = Question 3a: row 6 
 
The population: countries 
21 = Question 1: row 38 
 
22 and 18, 19, 20, 21 
3 Search strategy review questions 4 and 5 
4. What is the current national practice regarding screening for chronic HBV and HCV infection in each of the 34 
countries* in  
• pregnant women; 
• blood donors; 
• migrants; 
• IDUs; 
• MSM? 
5. What is the effectiveness of these screening programmes in terms of 
• process: coverage of the programme and the proportion of the risk group screened; 
• outcome: proportion of screened individuals found HBsAg- or HCV-RNA-positive;  
• outcome: proportion of positive individuals who are receiving care;  
• prevention of secondary cases: what proportion of contacts of HBsAg-positive individuals detected through 
screening is vaccinated? 
What is the cost-effectiveness of these screening programmes? 
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Search strategy Q4 and Q5 
Infection: hepatitis B or hepatitis C 
1 = Question 1: row 6 
 
Outcome: screening 
2 Screening 
3 Mass screening (MeSH) 
4 Testing 
5 or 2-4 
 
Outcome: national practice 
6 nation$ (national, nationwide) 
7 practice 
8 program$ (bv program, programme of programmatic)  
9 policy 
10 guidelines 
11 or 6-10 
 
Population: specific groups 
12 = Question 1: row 64 
 
Population: countries 
13 = Question 1: row 38 
 
14 and 1, 5, 11, 12, 13 
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Annex 3. Data extraction form 
First author:  ____________________ 
 Excluded Reason: ……………………… 
Publication year:  ______ 
1. Date extracted: … - … – 2009 
2. Extracted by: 
1  Susan 
2  Irene 
3. Type of publication 
1  Peer-reviewed publication 
2  Public health report 
3  Letter 
4  Other: ……………… 
4. Relevant for review question: 
1  Q1: Prevalence  
2  Q3: Burden of cirrhosis/HCC 
3  Q4: National screening practice 
4  Q5: Screening effectiveness 
5. Subject of the study: 
5a 1 □ HBV 2 □ HCV 3 □ HBV and HCV 
5b 1 □ cirrhosis 2 □ HCC 3 □ cirrhosis and HCC 
5c 1 □ screening  
6. Period of data collection: _________ – ________ 
6b. Country: 
1 □ Austria 13 □ Ireland 25 □ Spain 
2 □ Belgium 14 □ Italy 26 □ Sweden 
3 □ Bulgaria 15 □ Latvia 27 □ United Kingdom 
4 □ Cyprus 16 □ Lithuania 28 □ Norway 
5 □ Czech Republic 17 □ Luxembourg 29 □ Iceland 
6 □ Denmark 18 □ Malta 30 □ Liechtenstein 
7 □ Estonia 19 □ Netherlands 31 □ Switzerland 
8 □ Finland 20 □ Poland 32 □ Croatia 
9 □ France 21 □ Portugal 33 □ the former Yugoslav Republic of Macedonia 
10 □ Germany 22 □ Romania 34 □ Turkey 
11 □ Greece 23 □ Slovakia  
12 □ Hungary 24 □ Slovenia 35 □ multiple countries: …… 
 
7. Area in country: 
1 □ whole country 
2 □ region: ………… 
3 □ city: ………… 
4 □ not specified 
8. Geographical area: 
1 □ urban 
2 □ rural 
3 □ both 
4 □ not specified 
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9. Study population:   
1 □ general population: __________________ 
2 □ blood donors 
3 □ pregnant women 
4 □ drug users   
5 □ MSM: ______________ 
6 □ migrants → proceed to 10 and 11 
7 □ other: ……………….. 
(10 and 11 only for migrant study population) 
10. Country of origin:  
……………. …………………. 
……………. ………………… 
11. Generation:  
1 □ First generation migrants 
2 □ Second generation migrants   
3 □ First and second generation migrants 
4 □ Not specified 
12. Age groups included:  
1 □ children (0–17 years) 
2 □ adults (18 and older)  
3 □ both children and adults 
4 □ pregnant women 
5 □ not specified 
Quality criteria, external validity (representativeness of the sample for the target population) 
13. Study design:  
1 □ cross-sectional 
2 □ meta-analysis 
3 □ modelling 
4 □ other: ………… 
14. Sampling method: 
1 □ exhaustive (total population) 
□ probabilistic sample (random sample) 
 2 □ high quality 
 3 □ medium quality 
 4 □ low quality 
 5 □ no info on quality 
6 □ non-probabilistic sample (convenience sample) 
7 □ other: …………… 
8 □ not specified 
15. Type of sample:  
1 □ serum 
2 □ dried blood spots 
3 □ neonatal dried blood spots for pregnant women 
4 □ oral fluid 
5 □ other: …… 
16. Type of test : 
1 □ HBsAg (EIA)  
2 □ HBV DNA 
3 □ HBV rapid test 
4 □ Anti-HCV EIA  
5 □ Anti-HCV Immunoblot (RIBA) 
6 □ HCV-RNA 
7 □ HCV rapid test 
17. Outcome liver disease:  
1 □ Cirrhosis 2 □ HCC 3 □ both 
18. Outcome burden: 
1 □ morbidity – prevalence 
2 □ morbidity – incidence 
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3 □ mortality 
4 □ prevalence in patients 
(Only for review question 4 and 5: National screening practice and effectiveness) 
19. Type of screening program: 
1 □ universal screening 
2 □ screening of risk groups 
20. Condition screened for: 1 □ HBV 2 □ HCV 3 □ both 
21. Coverage: 1 □ Nationwide 2 □ Regional 
22. Targeted (risk) groups:  
1 □ general population 
2 □ blood donors 
3 □ pregnant women 
4 □ drug users 
5 □ MSM 
6 □ migrants; specify …… 
7 □ other: ………………… 
23. Outcome measures (effectiveness): 
1 □ coverage 
2 □ prevalence 
3 □ proportion of positives receiving care 
4 □ proportion of susceptibles vaccinated 
5 □ proportion of contacts vaccinated 
6 □ cost-effectiveness 
Results 
24. For cross-sectional studies: What was the participation rate? …… % 
25. Number of participants: …… 
26. Age of participants (not for pregnant women) 
Range: ____ – ______ median:_________ mean: __________ 
27. Age-specific results reported: 
1 □ Yes 
2 □ No 
Table 1a 
 Standardised n N % pos 95%CI Result text 
HBsAg       
HBV DNA       
Anti-HCV       
HCV-RNA       
Cirrhosis       
Cirrhosis: incidence       
HCC       
HCC: incidence       
 
Table 1b 
 Standardised n N % pos 95% CI Result text 
HBsAg       
HBV DNA       
Anti-HCV       
HCV-RNA       
Cirrhosis       
Cirrhosis: incidence       
HCC       
HCC: incidence       
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Table 1c 
 Standardised n N % pos 95% CI Result text 
HBsAg       
HBV DNA       
Anti-HCV       
HCV-RNA       
Cirrhosis       
Cirrhosis: incidence       
HCC       
HCC: incidence       
 
Table 2a 
(risk) group: n N % 95% CI Result text 
Coverage: % screened      
% susceptibles vaccinated       
% contacts vaccinated      
Cost-effectiveness      
 
Table 2b 
(risk) group: n N % 95% CI Result text 
Coverage: % screened      
% susceptibles vaccinated       
% contacts vaccinated      
Cost-effectiveness      
 
Table 2c 
(risk) group: n N % 95% CI Result text 
Coverage: % screened      
% susceptibles vaccinated       
% contacts vaccinated      
Cost-effectiveness      
 
28. Special interest: 
1 □ Yes 
2 □ No 
29. References:  
30. Remarks: 
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